3696.HK
T3InSilico Medicine Cayman TopCo
Key Reported Metrics, Reratings Triggers & ResultsAdjusted Loss (Non-IFRS) provides crucial insight into the company's operational efficiency and cost management, excluding non-cash and non-recurring items. A n
Upcoming print · 2026-08-26
| Key reported metrics | Rerating thresholds | ||||
|---|---|---|---|---|---|
| Metric | Last period | Why it matters | What's needed for rerating | Rerating context | Earnings date |
| Adjusted Loss (Non-IFRS) | +100.22% | Adjusted Loss (Non-IFRS) provides crucial insight into the company's operational efficiency and cost management, excluding non-cash and non-recurring items. A narrowing loss or slower growth in loss is essential for investor confidence, signaling progress towards profitability and sustainable operations. | For the stock to rerate higher, InSilico Medicine Cayman TopCo (3696.HK) needs to report an Adjusted Loss (Non-IFRS) that reflects a net profit of at least USD 45.5 million for the six months ended June 30, 2026. This would meet or exceed the lower end of the company's positive profit alert for adjusted non-IFRS net profit. | Achieving a net profit of at least USD 45.5 million signals a significant turnaround to profitability, validating InSilico's AI-driven drug discovery model and monetization of collaborations. This exceeds prior loss expectations, demonstrates operational efficiency, and boosts investor confidence in its long-term growth and competitive position in AI biotech. | |
| Software Revenue | +23.8% | Software Revenue highlights the commercialization success of InSilico's proprietary Pharma.AI platform. Strong growth in this segment indicates the platform's ability to generate recurring revenue independent of drug development milestones, validating its value and scalability in the market. | For the stock to rerate higher, InSilico Medicine Cayman TopCo (3696.HK) needs to report year-on-year Software Revenue growth of at least 150-200% for the first half of 2026. This would represent a substantial acceleration from the prior reported value of +23.8% and align with the company's overall revenue guidance of approximately 272.7% to 287.3% year-on-year for the same period. | Achieving this accelerated software revenue growth confirms strong adoption and monetization of InSilico's proprietary Pharma.AI platform. This validates the 'Biotech '26: AI Driven Drug Discovery' thesis, signaling significant market traction for its AI solutions, enhancing competitive position, justifying a higher valuation, and improving revenue visibility. | |
| Total Revenue | -34.48% | Total Revenue is a fundamental indicator of the company's overall business performance and market acceptance of its AI-driven drug discovery solutions and collaborations. Investors will closely monitor this metric for signs of recovery or continued decline, as it reflects the company's ability to monetize its technology and pipeline. | Total Revenue exceeding USD 106.5 million for the six months ended June 30, 2026, surpassing the high end of the company's own guidance range of approximately USD 102.5 million to USD 106.5 million. | Exceeding this guidance validates the successful monetization of InSilico Medicine's AI-driven drug discovery platforms and collaborations. It signals a strong reversal from prior negative revenue trends, accelerating the path to profitability and reinforcing investor confidence in its competitive edge within the rapidly expanding AI biotech sector. | |